Prevalence and predictors of pulmonary hypertension in patients with myeloproliferative neoplasms: single-center study

Abstract

Background Pulmonary hypertension is a major complication of several hematologic disorders including myeloproliferative neoplasms (MPNs). Despite the potential significance of PH to the management and prognosis of MPN, accurate estimates of its prevalence in MPNs and risk factors for the condition are poorly established. Aim To determine the prevalence of pulmonary hypertension in patients with MPNs at Sohag University Hospital and to analyze data of those patients to find predictors of pulmonary hypertension in our patients. Patients and methods A total of 120 patients were diagnosed with MPNs according to the revised 2016 WHO diagnostic criteria who attended the Outpatient Hematology Clinic at Sohag University Hospital in the period from April 2021 to October 2022. Systolic pulmonary artery pressure (SPAP) by using Transthoracic echocardiography (TTE) is determined in all MPNs patients enrolled in our study. Results The overall prevalence of PH in MPN patients was found to be 26.7%. We found a significant relationship between old age, long MPN duration since diagnosis, presence of PMF, anemia, leukocytosis, hyperuricemia, and occurrence of PH. Conclusion The prevalence of PH in patients with MPNs was 26.7%. According to MPNs subtypes, the highest PH prevalence was in PMF patients. Our findings suggest that old age, long MPNs duration since diagnosis, presence of PMF, and hyperuricemia are valuable for predicting PH occurrence in patients with MPNs.